Kinn Therapeutics

Kinn Therapeutics is a privately held preclinical service company based in Bergen, Norway. It specialises in xenograft cancer models, including immunocompetent patient-derived xenograft (PDX) models, and tracks tumour progression over time. Its services also cover in vivo and in vitro approaches to assess drug treatments across cancer types, companion imaging platforms, surrogate biomarker analysis, companion diagnostics and biomarker panels for clinical trials.

Its customers are developers of novel anticancer compounds, including small molecule inhibitors and immunotherapies. The company works with partners on tailored model systems and preclinical analysis of their targets and therapeutics, and sells these services on a project basis.

The company was founded in 2004 and is headquartered in Bergen. Its management team includes Emmet Mc Cormack, a professor at the University of Bergen who chairs the company, and co-founder Bjørn Tore Gjertsen, a professor at the University of Bergen and senior consultant hematologist at Haukeland University Hospital. The company is recruiting skilled researchers and technicians.

Product: Tailored preclinical oncology services, including PDX and xenograft models, in vivo and in vitro efficacy testing, imaging, and biomarker analysis